Last reviewed · How we verify
NCT05101460
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
trial testing XVIVO Perfusion System (XPS™) with STEEN Solution™ in Lung Transplant in 315 participants. Currently enrolling.
24 April 2024
Quick facts
| Lead sponsor | XVIVO Perfusion |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 315 |
| Start date | 29 October 2019 |
| Primary completion | 24 April 2024 |
| Estimated completion | 24 April 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- XVIVO Perfusion System (XPS™) with STEEN Solution™
Conditions studied
- Lung Transplant — all drugs for Lung Transplant →
Sponsor
XVIVO Perfusion — full company profile →
Who can join
18 and older, any sex, with Lung Transplant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The XVIVO Registry is to collect standard of care clinical data from "all-comers" who are transplanted with an EVLP lung treated with the XVIVO Perfusion System™ in order to assess the long-term performance of the device, and monitor device-related serious adverse events. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data. In addition, 4 and 5-year UNOS registry data of the 126 subjects who received an EVLP transplant under the NOVEL and NOVEL Extension studies are provided as part of the long-term safety and quality of life data.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05101460
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Transplant
Currently open trials in the same condition.
- NCT07035743 — Bronchial Response to Exercise After Double Lung Transplantation · recruiting
- NCT06476132 — Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients · Phase 2 · recruiting
- NCT06033196 — Tocilizumab in Lung Transplantation · Phase 2 · recruiting
- NCT05924113 — A Study of Latin Dance for Post- Lung Transplant · NA · recruiting
- NCT05898776 — 10°C vs 4°C Lung Preservation RCT · NA · active not recruiting
Other XVIVO Perfusion trials
Trials by the same sponsor.
- NCT03991923 — Non-ischemic Preservation of the Donor Heart in Heart Transplantation · NA · active not recruiting
- NCT04293744 — Acute Kidney Injury After Cardiac Surgery · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05101460 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by XVIVO Perfusion
- Last refreshed: 14 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05101460.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing